Pantomicina (Erythromycin Lactobionate)

Pantomicina (erythromycin lactobionate) is employed to treat bacterial infections affecting several organ systems.

• Respiratory tract infections: helps eradicate pathogens causing pneumonia, bronchitis and other lower airway infections.
• Skin and soft tissue infections: reduces bacterial load in cellulitis, abscesses and wound infections.
• Ear, nose, and throat infections: effective against otitis media, sinusitis and pharyngitis caused by susceptible organisms.
• Sexually transmitted infections (e.g., chlamydia): eliminates Chlamydia trachomatis when other agents are unsuitable.
• Prophylaxis of bacterial endocarditis: administered before certain dental or surgical procedures to prevent infection of heart valves.

• Erythromycin lactobionate binds to the 50S subunit of bacterial ribosomes, inhibiting the translocation step of protein synthesis. This blockade prevents elongation of the nascent peptide chain, halting bacterial growth and leading to a bacteriostatic effect against susceptible Gram‑positive and some Gram‑negative organisms.

Adverse reactions may occur with intravenous erythromycin lactobionate. Monitoring for side effects is recommended during therapy.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools, often self‑limiting.
• Abdominal pain: cramping or discomfort.
• Rash: mild skin erythema or itching.
• Elevated liver enzymes: transient increase in hepatic transaminases.
• Injection site pain: discomfort at the IV site.

Serious or Rare Side Effects

• Hepatotoxicity: signs of liver injury such as jaundice.
• Severe allergic reaction: anaphylaxis, angioedema, or bronchospasm.
• Cardiac arrhythmias: QT‑interval prolongation leading to torsades de pointes.
• Hemolytic anemia: destruction of red blood cells.
• Pseudomembranous colitis: Clostridioides difficile infection.
• Renal impairment: acute kidney injury in susceptible patients.

Before initiating Pantomicina, clinicians should assess patient history and monitor specific parameters.

• Hepatic function: evaluate liver enzymes and avoid use in severe hepatic impairment.
• Cardiac risk: avoid in patients with known QT prolongation or electrolyte disturbances.
• Renal function: adjust therapy in severe renal insufficiency.
• Drug allergies: confirm no known hypersensitivity to macrolides.
• Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Erythromycin lactobionate can alter the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid)

• Cisapride: risk of serious cardiac arrhythmias.
• Pimozide: may cause fatal ventricular arrhythmias.
• Statins (e.g., simvastatin, lovastatin): increased risk of rhabdomyolysis.
• Carbamazepine: reduced efficacy of carbamazepine.
• Warfarin: potentiation of anticoagulant effect, leading to bleeding.

Moderate Interactions (Monitor Closely)

• Digoxin: possible increase in serum digoxin levels.
• Theophylline: may raise theophylline concentrations.
• Oral contraceptives: reduced hormonal efficacy.
• Phenytoin: decreased phenytoin levels.
• Antacids containing aluminum or magnesium: may impair absorption of oral macrolides (not applicable to IV but noted for combination therapy).